Proposed experiment from debate on TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small
Background and Rationale
This experiment tests the hypothesis that G3BP proteins contribute to TDP-43 pathological aggregation through mechanisms independent of canonical stress granule formation. While G3BP1/2 are well-established stress granule nucleators, recent evidence suggests they may also facilitate protein aggregation through direct protein-protein interactions or alternative phase separation pathways. The study employs TDP-43 aggregation models that bypass stress granule induction, including chronic low-level expression of aggregation-prone TDP-43 mutants (A315T, M337V) or treatment with aggregation-promoting conditions (hyperosmotic stress, proteasome inhibition) that don't trigger typical stress responses. Primary neuronal cultures or differentiated motor neuron-like cells will be used with G3BP1/2 knocked down via siRNA or genetically deleted using CRISPR. The experimental design specifically avoids sodium arsenite or heat shock protocols that induce stress granules, instead focusing on conditions where TDP-43 aggregation occurs through intrinsic propensity or cellular aging processes. Aggregation will be quantified using filter trap assays, immunocytochemistry for phosphorylated TDP-43, and biochemical fractionation to separate soluble from insoluble protein pools. This approach will reveal whether G3BP proteins have aggregation-promoting roles beyond their stress granule functions.
This experiment directly tests predictions arising from the following hypotheses:
- Stress Granule Phase Separation Modulators
- Phase-Separated Organelle Targeting
- RNA Granule Nucleation Site Modulation
- Mitochondrial RNA Granule Rescue Pathway
- Axonal RNA Transport Reconstitution
Experimental Protocol
Phase 1: Cell Culture Preparation (Days 1-3)• Maintain HEK293T, SH-SY5Y, and primary cortical neurons in appropriate media
• Transfect cells with TDP-43 wildtype, A315T, and M337V constructs using Lipofectamine 3000
• Generate stable G3BP1/G3BP2 knockout cell lines using CRISPR-Cas9 (n=3 clones per line)
• Validate knockout efficiency by Western blot and qRT-PCR
Phase 2: G3BP Inhibition and TDP-43 Expression (Days 4-7)
• Treat cells with G3BP inhibitors: C108 (10-50 μM), ISRIB (200 nM), or siRNA knockdown
• Express TDP-43 constructs for 24-48 hours to induce aggregation
• Avoid stress conditions (no arsenite, heat shock, or oxidative stress)
• Monitor cell viability using MTT assay and trypan blue exclusion
Phase 3: TDP-43 Aggregation Analysis (Days 8-10)
• Fix cells at 24, 48, and 72 hours post-transfection
• Perform immunofluorescence using anti-TDP-43 (1:500) and anti-G3BP1 (1:200) antibodies
• Quantify cytoplasmic TDP-43 aggregates >1 μm diameter per cell (n≥200 cells/condition)
• Assess nuclear TDP-43 clearance by measuring nuclear/cytoplasmic fluorescence ratio
• Perform filter trap assays to quantify insoluble TDP-43 aggregates
Phase 4: Stress Response Assessment (Days 11-14)
• Subject cells to mild physiological stresses: 42°C heat shock (30 min), 100 μM H2O2 (1 hour), 1 μM tunicamycin (4 hours)
• Measure cell survival by ATP luminescence and caspase-3/7 activity
• Analyze stress response gene expression (HSP70, CHOP, XBP1) by qRT-PCR
• Assess protein synthesis recovery using puromycin incorporation assay
Phase 5: Alternative Nucleator Testing (Days 15-18)
• Overexpress alternative stress granule nucleators: CAPRIN1, USP10, or UBAP2L
• Co-transfect with TDP-43 constructs in G3BP-deficient cells
• Quantify rescue of stress response functionality
• Measure formation of ribonucleoprotein granules using FISH for specific mRNAs
Expected Outcomes
TDP-43 aggregation will persist in G3BP-inhibited cells, with ≥70% of transfected cells showing cytoplasmic aggregates regardless of G3BP status, demonstrating aggregation independence from stress granule machinery
G3BP inhibition will impair cellular stress responses by 40-60%, with reduced survival rates (p<0.01) and delayed protein synthesis recovery following physiological stress exposure
Nuclear TDP-43 clearance will be unaffected by G3BP status, maintaining similar nuclear depletion kinetics (50-70% reduction within 48 hours) across all treatment conditions
Alternative stress granule nucleators will partially rescue stress responses in G3BP-deficient cells, restoring 30-50% of normal stress tolerance when overexpressed
Insoluble TDP-43 aggregate formation will show <20% difference between G3BP-sufficient and G3BP-deficient conditions, measured by filter trap assay
Cell viability under basal conditions will remain >85% in G3BP-inhibited cells expressing TDP-43, indicating that aggregation toxicity is independent of G3BP-mediated pathwaysSuccess Criteria
•
Statistical significance threshold: p<0.05 for all comparisons with n≥3 biological replicates and ≥200 cells analyzed per condition
•
TDP-43 aggregation independence: <30% difference in aggregate formation between G3BP-sufficient and G3BP-deficient conditions across all TDP-43 variants
•
Stress response impairment: ≥30% reduction in stress survival or protein synthesis recovery in G3BP-inhibited cells compared to controls
•
Knockout validation: ≥90% reduction in G3BP1/G3BP2 protein levels confirmed by Western blot in all knockout clones used
•
Functional rescue criteria: Alternative nucleators must restore ≥25% of normal stress response functionality to be considered functionally relevant
•
Reproducibility requirement: Key findings must be replicated across at least 2 different cell types (HEK293T and neuronal cells) with consistent directional effects